EuroPCR 2022: CLASP TR among the trials to watch in the tricuspid space

1727

Transcatheter tricuspid valve repair potentially offers a “less risky” option for patients with tricuspid regurgitation (TR), according to Rebecca Hahn (New York, USA), discussing latest developments in the tricuspid field with Cardiovascular News at EuroPCR 2022 (17–20 May, Paris, France). 

In this video interview Hahn details the importance having transcatheter options for treating TR, as well as detailing findings from the CLASP TR early feasibility trial of the Pascal (Edwards Lifesciences) tricuspid repair device, which she presented during a late-breaking trial session at the EuroPCR meeting.  

Hahn also discusses the key trials to watch in the tricuspid space, which she says will be “extremely important” to the field. 


LEAVE A REPLY

Please enter your comment!
Please enter your name here